Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McCormick & Company, Incorporated (MKC) vs Stryker Corporation (SYK) Price & Performance

McCormick & Company, IncorporatedTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

McCormick & Company, Incorporated vs Stryker Corporation — how do they compare? McCormick & Company, Incorporated trades at $44.69 (market cap $12.39B), while Stryker Corporation trades at $278.72 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 8.6× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Stryker Corporation for 20 Days on average.

MKCSYK
Market Cap
$12.39B$106.24B
Volume
6,140,8722,982,001
Sector
Consumer StaplesHealth
52-Week High
$71.65$388.35
52-Week Low
$44.14$269.75
Typical Hold Time
67 Days20 Days
Enterprise Value
$17.07B$117.70B
Dividend Yield
4.18%1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McCormick & Company, Incorporated

MKC trades at $45.25, down 0.33% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 8.31. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Recent dividend declaration of $0.48 per share provides income support. Revenue growth has been steady, reaching $6.84B in 2025 with net income of $789.4M.

The stock presents value opportunity with below-sector P/E ratio and consistent profitability (19.39% net margin), though technical indicators signal near-term weakness. Analyst consensus is mixed with 33% buy ratings but $53.50 price target suggests 18% upside. Key risks include integration challenges from acquisitions and consumer spending sensitivity.

Stryker Corporation

Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.

Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MKC
100% Buy0% Sell
Avg holding period · 67 Days
SYK
1% Buy99% Sell
Avg holding period · 20 Days

Top news

Latest headlines on both assets

About McCormick & Company, Incorporated

In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.

Read more on MKC →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →